Luca Benatti - 26 Dec 2025 Form 4 Insider Report for Quince Therapeutics, Inc. (QNCX)

Role: Director
Signature: /s/ Brendan Hannah as attorney-in-fact for Luca Benatti
Issuer symbol: QNCX
Transactions as of: 26 Dec 2025
Net transactions value: -$173,500
Form type: 4
Filing time: 29 Dec 2025, 17:36:12 UTC
Previous filing: 06 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Benatti Luca	Director	C/O QUINCE THERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 273, SOUTH SAN FRANCISCO	/s/ Brendan Hannah as attorney-in-fact for Luca Benatti	29 Dec 2025	0001613842

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	QNCX	Common Stock	Sale	$173,500	-50,000	-56%	$3.47	39,179	26 Dec 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Content

The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.